Open AccessRole of Endocannabinoids on Neuroinflammation in Autism Spectrum Disorder Prevention
Author(s) -
Syed Shahid Habib,
Khalid Al-Regaiey,
Shahid Bashir,
Muhammad Iqbal
Publication year - 2017
Publication title -
journal of clinical and diagnostic research
Language(s) - English
Resource type - Journals
eISSN - 2249-782X
pISSN - 0973-709X
DOI - 10.7860/jcdr/2017/23862.9969
Subject(s) - neuroinflammation , endocannabinoid system , autism , autism spectrum disorder , neuroscience , mechanism (biology) , neurogenesis , psychology , disease , medicine , psychiatry , philosophy , receptor , epistemology
Autism Spectrum Disorder (ASD) disease has become a mounting socio-economical alarm around the world. Neuroinflammtion had been shown in postmortem brain specimens from ASD patients. The Endocannabinoids System (ES) consists of a family of locally produced, short-lived, endogenous, phospholipid-derived agonists (endocannabinoids) that control energy balance and body composition. The growing number of medical benefits of ES, such as their ability to regulate processes like neuroinflammation, neurogenesis and memory, raise the question of their potential role as a preventive treatment of ASD. To test this hypothesis, basic and clinical studies allow us a thorough investigation of the role of ES in the pathogenesis of ASD. This hypothesis will help to understand the mechanism of ES and its role in ASD.